The European Union on Thursday approved the highly contentious Alzheimer's medication Kisunla under strict conditions, with the drug's effectiveness hotly debated by the medical community.
Fact‑first reporting that puts you at the heart of the newsroom. Subscribe for full access.
- Unlimited access to all premium content
- Uninterrupted ad-free browsing experience
- Mobile-optimized reading experience
- Weekly Newsletters
- MPesa, Airtel Money and Cards accepted